Clinical Trials on Prostate Cancer Patients With Bone Metastasis

Total 1447 results

Astellas Pharma Inc

Completed

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Metastatic Castration Resistant Prostate Cancer

India
Tufts Medical Center
Bayer; Ohio State University Comprehensive Cancer Center; Lahey Clinic; Henry Ford...

Active, not recruiting

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

Metastatic Castrate Resistant Prostate Cancer

United States
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States, Italy, Spain, Belgium, Canada, France, Korea, Republic of, United Kingdom, Brazil, Czechia, Turkey, Australia, Chile, Germany, Japan, Netherlands, Slovakia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Terminated

To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

China
Peking Union Medical College Hospital

Completed

177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

China
Amgen

Completed

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States, Belgium, Austria, Singapore, Australia, Netherlands, France, Japan, Taiwan, Canada
ARTBIO Inc.

Completed

Phase 0/1 Study of 212Pb-NG001 in mCRPC

Metastatic Castration-resistant Prostate Cancer

Norway
Tceleron Therapeutics, Inc.

Terminated

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States
Peter MacCallum Cancer Centre, Australia

Completed

PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) (PRINCE)

Metastatic Castration Resistant Prostate Cancer

Australia
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer
Syntrix Biosystems, Inc.
National Cancer Institute (NCI)

Recruiting

Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (SYNERGY-201)

Metastatic Castration-resistant Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

Metastatic Castration-resistant Prostate Cancer

United States
Bayer

Recruiting

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

United Kingdom, Netherlands, Finland
Fusion Pharmaceuticals Inc.

Recruiting

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). (TATCIST)

Metastatic Castration Resistant Prostate Cancer

United States
Aragon Pharmaceuticals, Inc.

Active, not recruiting

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms | Metastatic Castration-Resistant Prostate Cancer

United States, Canada, Netherlands, United Kingdom
Bayer

Active, not recruiting

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer (REASSURE)

Metastatic Castration-resistant Prostate Cancer

United States, Austria, Czechia, Israel, Italy, Germany, United Kingdom, France, Mexico, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Denmark, Sweden, Argentina, Portugal
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Active, not recruiting

A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

Prostatic Neoplasms | Metastatic Castration-Resistant Prostate Cancer

Japan
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetics, Inc.; Foundation Medicine, Inc.

Active, not recruiting

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Metastatic Castration-resistant Prostate Cancer

China
POINT Biopharma, a wholly owned subsidiary of Eli...

Active, not recruiting

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

Metastatic Castration-Resistant Prostate Cancer

United States, Canada, Netherlands, Sweden, France, United Kingdom
Hinova Pharmaceuticals Aus Pty Ltd

Completed

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Australia
Dana-Farber Cancer Institute
Eli Lilly and Company; Genentech, Inc.

Active, not recruiting

Abemaciclib With or Without Atezolizumab for mCRPC

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Australian and New Zealand Urogenital and Prostate...
Astellas Pharma Inc; Endocyte; Prostate Cancer Research Alliance; National Health...

Active, not recruiting

Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer (ENZA-p)

Metastatic Castration-Resistant Prostate Cancer

Australia
Pfizer
In Expanded Access, treating physicians are the Sponsors

Available

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Metastatic Castration-Resistant Prostate Cancer
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetics, Inc.; Foundation Medicine, Inc.

Completed

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Metastatic Castration-resistant Prostate Cancer

United States, Canada, Denmark, Germany, Italy, Netherlands, Norway, Spain, Argentina, Taiwan, France, Korea, Republic of, Brazil, Japan, Turkey, United Kingdom, Austria, Australia, Israel, Sweden
AB Science

Completed

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Metastatic Castrate Resistant Prostate Cancer

Italy, Russian Federation, India, Canada, France, Malaysia
Université de Sherbrooke
Canadian Cancer Society (CCS); Fonds de la Recherche en Santé du Québec; Merck... and other collaborators

Completed

3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Canada
Tceleron Therapeutics, Inc.

Terminated

A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma in the Soft Tissue | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States, Puerto Rico
Paul Viscuse

Not yet recruiting

Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)

Metastatic Prostate Cancer | Castrate Sensitive Prostate Cancer

United States
Aarhus University Hospital
Rigshospitalet, Denmark

Terminated

A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer (DAPROCA-1)

Prostate Cancer | Metastasis

Denmark
Bayer

Recruiting

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA)

Advanced Metastatic Castration-resistant Prostate Cancer | Prostate Specific Membrane Antigen (PSMA) Expression

Canada, United Kingdom, Belgium
UMC Utrecht
Isala

Completed

Feasibility of Combined Focused Ultrasound and Radiotherapy Treatment in Patients With Painful Bone Metastasis (PRE-FURTHER)

Quality of Life | Pain | Neoplasm Metastasis | Bone Cancer | Bone Metastases | Tumor | Radiation Toxicity | Bone Neoplasm | Bone Lesion | Cancer Induced Bone Pain

Netherlands
Immunicon

Unknown

Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy (IMMC-38)

Prostate Cancer | Hormone Refractory Prostate Cancer

United States
Jonsson Comprehensive Cancer Center

Recruiting

Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Celcuity Inc

Recruiting

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | Genital Diseases, Male | Prostatic Disease | mCRPC (Metastatic Castration-resistant Prostate Cancer) | Urogenital Diseases, Male

United States, France, Spain, United Kingdom
Institut National de la Santé Et de la Recherche...
European Commission; Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Long Term Neurocognitive Effects of Low-dose Radiation in the Brain: Study of 150 Patients in the French Hemangioma Cohort (CogRad)

Patients Treated by Radiotherapy With < One Gy to the Brain

France
Novartis

Completed

Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid

Breast Cancer With Metastatic Bone Disease

Turkey
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Bone Metastases | Lung Metastases | HER2-positive Breast Cancer | Liver Metastases | Stage IV Breast Cancer | Recurrent Breast Cancer | Soft Tissue Metastases

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions

Breast Cancer With Bone Metastasis

Italy
Emory University
National Cancer Institute (NCI); Xencor, Inc.

Recruiting

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Castration-Sensitive Prostate Carcinoma

United States
Lawson Health Research Institute
University of Western Ontario, Canada; Lawson Health Research Institute Internal...

Completed

Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer

Prostate Cancer | Bone Loss

Canada
Michael Graham PhD, MD
University of Iowa; Holden Comprehensive Cancer Center

Active, not recruiting

68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer

Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer Metastatic

United States
The First Affiliated Hospital of Xiamen University

Recruiting

Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer, mCRPC

China
University of Pennsylvania
Prostate Cancer Foundation

Recruiting

TmPSMA-02 in mCRPC

Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

United States
Fundacion Oncosur

Recruiting

Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) (PEAPOD_FOS)

Prostate Cancer Metastatic

Spain
Peter MacCallum Cancer Centre, Australia

Recruiting

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer (AlphaBet)

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | mCRPC

Australia
Bayer

Recruiting

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Non-metastatic Castration-resistant Prostate Cancer

India
Telix Pharmaceuticals (Innovations) Pty Ltd

Recruiting

The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only (PROSTACT)

Metastatic Prostate Cancer

Australia, New Zealand
British Columbia Cancer Agency

Recruiting

PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA (PROTRACT)

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Canada
Hookipa Biotech GmbH

Terminated

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Metastatic

United States

Clinical Trials on Prostate Cancer Patients With Bone Metastasis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations